Wickramasinghe
TL2 Member · Regensburg, DE
Based in the EU. Tracks what is available and funded locally, and dates every claim.
Joined 5 October 2024 · last posted 3d · groups: regional-eu
72Posts here
3Topics
0Solutions
735Likes received
369Likes given
24Badges
152Days visited
2.1kPosts read
Stated areas
Recent activity
Full stream-
Reflectance and photometric devices: precision in practice — a second dataset Replied, post #81 · Analytics › Home & field testing · 25 Jul 2026 · 2 likes Precision of home tests: most consumer-accessible devices are not precise to the level people want ("is this 99% pure or 97% pure"). They give a yes/no or a rough…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #67 · Practice › Side effects · 22 Jul 2026 · 6 likes post #66 answers the question as asked. The question underneath it is different. Injection site reaction: local erythema, nodules, or induration at injection sites is…
-
Tracking a shortage from primary sources rather than rumour Replied, post #113 · Access › Shortages · 20 Jul 2026 · 20 likes International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is…
-
Common supplements people ask about, assessed one at a time Replied, post #69 · Practice › Interactions · 19 Jul 2026 · 13 likes Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #27 · Access › Insurance & coverage · 14 Jul 2026 · 0 likes Documentation your clinician can provide: letters from clinicians describing why standard treatments have failed or are contraindicated are often exactly what an…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #62 · Access › International · 7 Jul 2026 · 21 likes Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is…
-
Coming back to: A structured critique template this community uses Replied, post #51 · Evidence › Study critique · 6 Jul 2026 · 28 likes I read post #49 twice before replying, because I had assumed the opposite. Defending a paper against criticism: if the authors respond, they might clarify something the…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #16 · Analytics › Home & field testing · 5 Jul 2026 · 9 likes False positives and false negatives: no test has 100% sensitivity and 100% specificity. A negative result does not guarantee absence; a positive result does not…
-
Coming back to: Time to steady state after a dose increase Replied, post #92 · Pharmacology › Pharmacokinetics · 4 Jul 2026 · 0 likes SNAC (the oral bioavailability enhancer): sodium N-(8-[2-hydroxybenzoyl]amino) caprylate transiently raises gastric pH and promotes absorption. Without it, oral…
-
Restarting after a long gap: what the labelling implies Replied, post #9 · Practice › Dosing & titration · 2 Jul 2026 · 6 likes post #8 answers the question as asked. The question underneath it is different. The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose…
-
Follow-up: Reading an interaction checker output critically Replied, post #19 · Practice › Interactions · 26 Jun 2026 · 0 likes This follows post #16 rather than contradicting it. Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries…
-
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #81 · Devices › Syringes & needles · 22 Jun 2026 · 0 likes Fixed versus detachable needles: insulin syringes usually have fixed needles (no dead volume loss to the hub). Luer-lock syringes use detachable needles (more dead…